ROIV · Insider Trading

Roivant Sciences Ltd. Common Shares

Every open-market purchase and sale reported by ROIV officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Form 4 Filings
50
most recent
Open-Market Buys
0
code P
Sales
6
code S
Reporting Insiders
15
current holders
ROIV — Recent Form 4 Transactions (latest 2026-11-18)
FiledInsiderRole TypeSharesValue
2026-11-18 Keith S Manchester Director MIXED −4,418,520 −$53.54M
2026-11-18 QVT Financial LP — MIXED −4,418,520 −$53.54M
2026-11-18 Daniel Allen Gold Director MIXED −4,418,520 −$53.54M
2026-11-12 Eric Venker President & Immunovant CEO Sell −187,943 −$7.62M
2026-11-12 Frank Torti President and Vant Chair MIXED −1,188,943 −$48.79M
2026-11-12 Richard Pulik CFO MIXED −47,635 −$11.50M
2026-11-12 Mayukh Sukhatme President & CIO MIXED −167,181 −$6.86M
2026-11-12 Matthew Gline CEO MIXED −157,907 −$6.48M
2026-11-05 Eric Venker President & Immunovant CEO Sell −200,000 −$7.26M
2026-10-30 Eric Venker President & Immunovant CEO Sell −200,000 −$7.32M
2026-10-27 Ilan Oren Director A +810 —
2026-10-27 James C Momtazee Director MIXED +306 −$2.81K
2026-10-27 Epperly Melissa B, Director MIXED +397 −$4.23K
2026-10-22 Eric Venker President & Immunovant CEO Sell −200,000 −$7.02M
2026-10-20 Mayukh Sukhatme President & CIO F −19,976 −$669.80K
2026-10-20 Matthew Gline CEO F −34,638 −$1.16M
2026-10-05 Epperly Melissa B, Director MIXED — −$561.70K
2026-10-02 Frank Torti President and Vant Chair F +40,309 +$1.47M
2026-10-02 Mayukh Sukhatme President & CIO F −46,879 −$1.71M
2026-10-02 Matthew Gline CEO F −76,171 −$2.79M
2026-10-02 Eric Venker President & Immunovant CEO MIXED — −$6.55M
2026-09-22 Richard Pulik CFO F −2,129 −$84.67K
2026-09-22 Jennifer Humes Chief Accounting Officer F −3,880 −$154.31K
2026-09-18 Meghan Fitzgerald Director A +5,054 —
2026-09-18 Daniel Allen Gold Director A +5,054 —
2026-09-18 James C Momtazee Director A +5,054 —
2026-09-18 Ilan Oren Director A +5,054 —
2026-09-18 Keith S Manchester Director A +5,054 —
2026-09-18 Epperly Melissa B, Director A +5,054 —
2026-09-17 Meghan Fitzgerald Director Sell −5,112 −$203.15K
2026-09-17 Epperly Melissa B, Director Sell −4,938 −$196.23K
2026-09-14 Meghan Fitzgerald Director F −1,743 −$71.36K
2026-09-14 James C Momtazee Director F −2,905 −$118.93K
2026-09-14 Ilan Oren Director F −2,378 −$97.36K
2026-09-14 Daniel Allen Gold Director F −5,133 −$210.15K
2026-09-14 Epperly Melissa B, Director F −2,179 −$89.21K
2026-09-10 Meghan Fitzgerald Director MIXED — −$622.00K
2026-09-01 Eric Venker President & Immunovant CEO MIXED — −$6.38M
2026-08-24 Eric Venker President & Immunovant CEO F −13,909 −$512.41K
2026-08-24 Richard Pulik CFO F −5,749 −$211.79K
2026-08-21 Mayukh Sukhatme President & CIO MIXED — −$11.07M
2026-08-18 Mayukh Sukhatme President & CIO MIXED — −$21.60M
2026-07-29 Eric Venker President & Immunovant CEO MIXED — −$6.22M
2026-07-21 James C Momtazee Director A +405 —
2026-07-21 Ilan Oren Director A +775 —
2026-07-21 Epperly Melissa B, Director A +543 —
2026-07-02 Matthew Gline CEO F −76,171 −$2.70M
2026-07-02 Frank Torti President and Vant Chair F −40,310 −$1.43M
2026-07-02 Mayukh Sukhatme President & CIO F −46,878 −$1.66M
2026-07-02 Meghan Fitzgerald Director MIXED — −$261.00K
ROIV — Current Insider Holders
InsiderRole Shares HeldValue
Vivek Ramaswamy 10%+ Owner 47,011,612 $1.84B
Daniel Allen Gold Director 28,270,369 $1.11B
Keith S Manchester Director 21,058,011 $824.95M
Mayukh Sukhatme President & CIO 20,054,401 $785.63M
QVT Financial LP — 19,304,554 $756.26M
Matthew Gline CEO 16,391,229 $642.13M
Frank Torti President and Vant Chair 12,306,950 $482.12M
Eric Venker President & Immunovant CEO 811,211 $31.78M
Richard Pulik CFO 222,046 $8.70M
Rakhi Kumar Chief Accounting Officer 162,306 $6.36M
Ilan Oren Director 124,490 $4.88M
James C Momtazee Director 112,265 $4.40M
Jennifer Humes Chief Accounting Officer 106,419 $4.17M
Meghan Fitzgerald Director 41,162 $1.61M
Epperly Melissa B, Director 15,351 $601.38K
ROIV Insider Trading FAQ
Who are the insiders at ROIV?
15 officers, directors and 10%+ beneficial owners currently report holdings in ROIV via SEC Form 4.
Are ROIV insiders buying or selling?
Across the 50 most recent Form 4 filings for ROIV, 0 were open-market purchases (code P) and 6 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is ROIV insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent ROIV filing is dated 2026-11-18.
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the ROIV quote page; the site-wide leaderboard is on the insider transactions hub.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.